Clinical Trials · NCT02505334
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 635
- Start date
- Jul 2015
- Locations
- 47 sites, Japan
- Primary endpoint
- Change in Glycosylated Haemoglobin (HbA1c) (Week 26)